Vorinostat
Back to searchMolecule Structure
Scientific Name
Vorinostat
Description of the Drug
Vorinostat is a histone deacetylase (HDAC) inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma (CTCL) following prior systemic therapies.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB02546
http://www.drugbank.ca/drugs/DB02546
Brand Name(s)
Zolinza
Company Owner(s)
Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Histone deacetylase 6 | SINGLE PROTEIN | INHIBITOR | CHEMBL1865 |
Histone deacetylase 1 | SINGLE PROTEIN | INHIBITOR | CHEMBL325 |
Histone deacetylase 3 | SINGLE PROTEIN | INHIBITOR | CHEMBL1829 |
Histone deacetylase 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL1937 |
Clinical Trial(s)
Unichem Links
Atlas | SAHA | vorinostat | |||||
SureChEMBL | SCHEMBL9018 | ||||||
PharmGKB | PA164748224 | ||||||
Human Metabolome Database | HMDB0015568 | ||||||
DrugBank | DB02546 | ||||||
PubChem: Thomson Pharma | 14823867 | ||||||
PubChem | 5311 | ||||||
Mcule | MCULE-4234367506 | ||||||
NMRShiftDB | 80021416 | ||||||
LINCS | LSM-3828 | ||||||
Nikkaji | J653.349C | ||||||
PDBe | SHH | ||||||
BindingDB | 19149 | ||||||
EPA CompTox Dashboard | DTXSID6041133 | ||||||
DrugCentral | 4124 | ||||||
Brenda | 7817 | 1547 | 217024 | 41261 | 237067 | 206568 | 151869 |
ChemicalBook | CB3506806 | ||||||
Guide to Pharmacology | 6852 | ||||||
rxnorm | VORINOSTAT | ZOLINZA | |||||
PubChem: Drugs of the Future | 12015019 | ||||||
ChEBI | 45716 | ||||||
ZINC | ZINC000001543873 |